Efficacy of theophylline plus salmeterol/fluticasone propionate combination therapy in patients with asthma
Summary Objective To compare the efficacy of theophylline plus salmeterol/fluticasone propionate combination product (SFC) with SFC plus placebo in asthmatic patients. Methods In this randomized, stratified, parallel-group study, 325 patients were randomized to receive either 200 mg theophylline plu...
Gespeichert in:
| Veröffentlicht in: | Respiratory medicine 2013-03, Vol.107 (3), p.347-354 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 354 |
|---|---|
| container_issue | 3 |
| container_start_page | 347 |
| container_title | Respiratory medicine |
| container_volume | 107 |
| creator | Nie, Hanxiang Zhang, Guqin Liu, Min Ding, Xuhong Huang, Yi Hu, Suping |
| description | Summary Objective To compare the efficacy of theophylline plus salmeterol/fluticasone propionate combination product (SFC) with SFC plus placebo in asthmatic patients. Methods In this randomized, stratified, parallel-group study, 325 patients were randomized to receive either 200 mg theophylline plus 50/250 μg SFC or placebo tablet plus 50/250 μg SFC twice daily for 24 weeks. Outcome variables included the level of asthma control (assessed by the Asthma Control Test) and the number of patients experiencing ≥1 exacerbations during the 24-week treatment period. Testing of lung function as well as measurement of the levels of inflammatory markers in induced sputum was performed. Results There were significantly fewer patients with ≥1 asthma exacerbation in the theophylline plus SFC group (29.6%) when compared with the SFC plus placebo group (46.9%) ( p = 0.004). Theophylline plus SFC improved the FEF25–75% value, which indicates enhanced small airway function, to a greater extent than SFC plus placebo (66.9 ± 18.8% and 57.4 ± 17.6%, respectively; p |
| doi_str_mv | 10.1016/j.rmed.2012.12.004 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1312174652</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0954611112004544</els_id><sourcerecordid>1312174652</sourcerecordid><originalsourceid>FETCH-LOGICAL-c483t-f9fae2965c54e46f337127c8b13695271605801c556cc2d88fcf538b9ca493f93</originalsourceid><addsrcrecordid>eNp9UsuKFDEULURx2tEfcCEFbtxUT95dARFkGB8w4EJdh3T6hk5PqlImKaX-3lv0DMIshEAe95zDzTm3aV5TsqWEqqvTNg9w2DJC2RYXIeJJs6GSs44TJZ42G6Kl6BSl9KJ5UcqJEKKFIM-bC8aZJlSKTXN3431w1i1t8m09QpqOS4xhhHaKc2mLjQNUyCle-ThXRJa01nKaQhpthdalYR_whNeVn-20tGFsJ3yBsZb2T6jH1pZ6HOzL5pm3scCr-_2y-fnp5sf1l-722-ev1x9vOyd6XjuvvQWmlXRSgFCe8x1lO9fvKVdash1VRPaEOimVc-zQ9955yfu9dlZo7jW_bN6ddbHNXzOUaoZQHMRoR0hzMZRTRndCSYbQt4-gpzTnEbszlPUabVQ7iih2RrmcSsngzZTDYPNiKDFrFOZk1ijMGgUSDUaBpDf30vN-rT1QHrxHwPszANCL3wGyKQ49c3AIGVw1hxT-r__hEd1hbphQvIMFyr9_mIIE830dhnUWKEO2FIL_BQt3r7w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1289064671</pqid></control><display><type>article</type><title>Efficacy of theophylline plus salmeterol/fluticasone propionate combination therapy in patients with asthma</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Nie, Hanxiang ; Zhang, Guqin ; Liu, Min ; Ding, Xuhong ; Huang, Yi ; Hu, Suping</creator><creatorcontrib>Nie, Hanxiang ; Zhang, Guqin ; Liu, Min ; Ding, Xuhong ; Huang, Yi ; Hu, Suping</creatorcontrib><description>Summary Objective To compare the efficacy of theophylline plus salmeterol/fluticasone propionate combination product (SFC) with SFC plus placebo in asthmatic patients. Methods In this randomized, stratified, parallel-group study, 325 patients were randomized to receive either 200 mg theophylline plus 50/250 μg SFC or placebo tablet plus 50/250 μg SFC twice daily for 24 weeks. Outcome variables included the level of asthma control (assessed by the Asthma Control Test) and the number of patients experiencing ≥1 exacerbations during the 24-week treatment period. Testing of lung function as well as measurement of the levels of inflammatory markers in induced sputum was performed. Results There were significantly fewer patients with ≥1 asthma exacerbation in the theophylline plus SFC group (29.6%) when compared with the SFC plus placebo group (46.9%) ( p = 0.004). Theophylline plus SFC improved the FEF25–75% value, which indicates enhanced small airway function, to a greater extent than SFC plus placebo (66.9 ± 18.8% and 57.4 ± 17.6%, respectively; p < 0.001). A significant decrease in eosinophil count and concentration of eosinophil cationic protein in induced sputum was also seen in the theophylline plus SFC group when compared with the SFC plus placebo group (4.1 ± 2.2% and 6.3 ± 2.7%, 63.6 ± 39.5 μg/L and 89.4 ± 45.6 μg/L, respectively; all p < 0.01). Conclusion The combination of theophylline plus SFC may provide greater protection against asthma exacerbations, and its administration is accompanied by significant improvements in small airway function and airway inflammation.</description><identifier>ISSN: 0954-6111</identifier><identifier>EISSN: 1532-3064</identifier><identifier>DOI: 10.1016/j.rmed.2012.12.004</identifier><identifier>PMID: 23290154</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Adolescent ; Adult ; Aged ; Airway inflammation ; Albuterol - analogs & derivatives ; Albuterol - therapeutic use ; Androstadienes - therapeutic use ; Asthma ; Asthma - drug therapy ; Asthma - metabolism ; Asthma - physiopathology ; Bronchodilator Agents - therapeutic use ; Circadian Rhythm - physiology ; Drug Combinations ; Drug dosages ; Drug Therapy, Combination ; Female ; Fluticasone-Salmeterol Drug Combination ; Glucocorticoids - therapeutic use ; Hospitals ; Humans ; Inflammation Mediators - metabolism ; Male ; Middle Aged ; Peak Expiratory Flow Rate - drug effects ; Peak Expiratory Flow Rate - physiology ; Pulmonary/Respiratory ; Respiratory Mechanics - drug effects ; Respiratory Mechanics - physiology ; Salmeterol/fluticasone propionate combination product ; Small airway function ; Sputum - chemistry ; Standard deviation ; Theophylline ; Theophylline - therapeutic use ; Treatment Outcome ; Young Adult</subject><ispartof>Respiratory medicine, 2013-03, Vol.107 (3), p.347-354</ispartof><rights>Elsevier Ltd</rights><rights>2012 Elsevier Ltd</rights><rights>Copyright © 2012 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c483t-f9fae2965c54e46f337127c8b13695271605801c556cc2d88fcf538b9ca493f93</citedby><cites>FETCH-LOGICAL-c483t-f9fae2965c54e46f337127c8b13695271605801c556cc2d88fcf538b9ca493f93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0954611112004544$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23290154$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nie, Hanxiang</creatorcontrib><creatorcontrib>Zhang, Guqin</creatorcontrib><creatorcontrib>Liu, Min</creatorcontrib><creatorcontrib>Ding, Xuhong</creatorcontrib><creatorcontrib>Huang, Yi</creatorcontrib><creatorcontrib>Hu, Suping</creatorcontrib><title>Efficacy of theophylline plus salmeterol/fluticasone propionate combination therapy in patients with asthma</title><title>Respiratory medicine</title><addtitle>Respir Med</addtitle><description>Summary Objective To compare the efficacy of theophylline plus salmeterol/fluticasone propionate combination product (SFC) with SFC plus placebo in asthmatic patients. Methods In this randomized, stratified, parallel-group study, 325 patients were randomized to receive either 200 mg theophylline plus 50/250 μg SFC or placebo tablet plus 50/250 μg SFC twice daily for 24 weeks. Outcome variables included the level of asthma control (assessed by the Asthma Control Test) and the number of patients experiencing ≥1 exacerbations during the 24-week treatment period. Testing of lung function as well as measurement of the levels of inflammatory markers in induced sputum was performed. Results There were significantly fewer patients with ≥1 asthma exacerbation in the theophylline plus SFC group (29.6%) when compared with the SFC plus placebo group (46.9%) ( p = 0.004). Theophylline plus SFC improved the FEF25–75% value, which indicates enhanced small airway function, to a greater extent than SFC plus placebo (66.9 ± 18.8% and 57.4 ± 17.6%, respectively; p < 0.001). A significant decrease in eosinophil count and concentration of eosinophil cationic protein in induced sputum was also seen in the theophylline plus SFC group when compared with the SFC plus placebo group (4.1 ± 2.2% and 6.3 ± 2.7%, 63.6 ± 39.5 μg/L and 89.4 ± 45.6 μg/L, respectively; all p < 0.01). Conclusion The combination of theophylline plus SFC may provide greater protection against asthma exacerbations, and its administration is accompanied by significant improvements in small airway function and airway inflammation.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Airway inflammation</subject><subject>Albuterol - analogs & derivatives</subject><subject>Albuterol - therapeutic use</subject><subject>Androstadienes - therapeutic use</subject><subject>Asthma</subject><subject>Asthma - drug therapy</subject><subject>Asthma - metabolism</subject><subject>Asthma - physiopathology</subject><subject>Bronchodilator Agents - therapeutic use</subject><subject>Circadian Rhythm - physiology</subject><subject>Drug Combinations</subject><subject>Drug dosages</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Fluticasone-Salmeterol Drug Combination</subject><subject>Glucocorticoids - therapeutic use</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Inflammation Mediators - metabolism</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Peak Expiratory Flow Rate - drug effects</subject><subject>Peak Expiratory Flow Rate - physiology</subject><subject>Pulmonary/Respiratory</subject><subject>Respiratory Mechanics - drug effects</subject><subject>Respiratory Mechanics - physiology</subject><subject>Salmeterol/fluticasone propionate combination product</subject><subject>Small airway function</subject><subject>Sputum - chemistry</subject><subject>Standard deviation</subject><subject>Theophylline</subject><subject>Theophylline - therapeutic use</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>0954-6111</issn><issn>1532-3064</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UsuKFDEULURx2tEfcCEFbtxUT95dARFkGB8w4EJdh3T6hk5PqlImKaX-3lv0DMIshEAe95zDzTm3aV5TsqWEqqvTNg9w2DJC2RYXIeJJs6GSs44TJZ42G6Kl6BSl9KJ5UcqJEKKFIM-bC8aZJlSKTXN3431w1i1t8m09QpqOS4xhhHaKc2mLjQNUyCle-ThXRJa01nKaQhpthdalYR_whNeVn-20tGFsJ3yBsZb2T6jH1pZ6HOzL5pm3scCr-_2y-fnp5sf1l-722-ev1x9vOyd6XjuvvQWmlXRSgFCe8x1lO9fvKVdash1VRPaEOimVc-zQ9955yfu9dlZo7jW_bN6ddbHNXzOUaoZQHMRoR0hzMZRTRndCSYbQt4-gpzTnEbszlPUabVQ7iih2RrmcSsngzZTDYPNiKDFrFOZk1ijMGgUSDUaBpDf30vN-rT1QHrxHwPszANCL3wGyKQ49c3AIGVw1hxT-r__hEd1hbphQvIMFyr9_mIIE830dhnUWKEO2FIL_BQt3r7w</recordid><startdate>20130301</startdate><enddate>20130301</enddate><creator>Nie, Hanxiang</creator><creator>Zhang, Guqin</creator><creator>Liu, Min</creator><creator>Ding, Xuhong</creator><creator>Huang, Yi</creator><creator>Hu, Suping</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U9</scope><scope>ASE</scope><scope>FPQ</scope><scope>H94</scope><scope>K6X</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>20130301</creationdate><title>Efficacy of theophylline plus salmeterol/fluticasone propionate combination therapy in patients with asthma</title><author>Nie, Hanxiang ; Zhang, Guqin ; Liu, Min ; Ding, Xuhong ; Huang, Yi ; Hu, Suping</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c483t-f9fae2965c54e46f337127c8b13695271605801c556cc2d88fcf538b9ca493f93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Airway inflammation</topic><topic>Albuterol - analogs & derivatives</topic><topic>Albuterol - therapeutic use</topic><topic>Androstadienes - therapeutic use</topic><topic>Asthma</topic><topic>Asthma - drug therapy</topic><topic>Asthma - metabolism</topic><topic>Asthma - physiopathology</topic><topic>Bronchodilator Agents - therapeutic use</topic><topic>Circadian Rhythm - physiology</topic><topic>Drug Combinations</topic><topic>Drug dosages</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Fluticasone-Salmeterol Drug Combination</topic><topic>Glucocorticoids - therapeutic use</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Inflammation Mediators - metabolism</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Peak Expiratory Flow Rate - drug effects</topic><topic>Peak Expiratory Flow Rate - physiology</topic><topic>Pulmonary/Respiratory</topic><topic>Respiratory Mechanics - drug effects</topic><topic>Respiratory Mechanics - physiology</topic><topic>Salmeterol/fluticasone propionate combination product</topic><topic>Small airway function</topic><topic>Sputum - chemistry</topic><topic>Standard deviation</topic><topic>Theophylline</topic><topic>Theophylline - therapeutic use</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nie, Hanxiang</creatorcontrib><creatorcontrib>Zhang, Guqin</creatorcontrib><creatorcontrib>Liu, Min</creatorcontrib><creatorcontrib>Ding, Xuhong</creatorcontrib><creatorcontrib>Huang, Yi</creatorcontrib><creatorcontrib>Hu, Suping</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Virology and AIDS Abstracts</collection><collection>British Nursing Index</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>British Nursing Index</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Respiratory medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nie, Hanxiang</au><au>Zhang, Guqin</au><au>Liu, Min</au><au>Ding, Xuhong</au><au>Huang, Yi</au><au>Hu, Suping</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy of theophylline plus salmeterol/fluticasone propionate combination therapy in patients with asthma</atitle><jtitle>Respiratory medicine</jtitle><addtitle>Respir Med</addtitle><date>2013-03-01</date><risdate>2013</risdate><volume>107</volume><issue>3</issue><spage>347</spage><epage>354</epage><pages>347-354</pages><issn>0954-6111</issn><eissn>1532-3064</eissn><abstract>Summary Objective To compare the efficacy of theophylline plus salmeterol/fluticasone propionate combination product (SFC) with SFC plus placebo in asthmatic patients. Methods In this randomized, stratified, parallel-group study, 325 patients were randomized to receive either 200 mg theophylline plus 50/250 μg SFC or placebo tablet plus 50/250 μg SFC twice daily for 24 weeks. Outcome variables included the level of asthma control (assessed by the Asthma Control Test) and the number of patients experiencing ≥1 exacerbations during the 24-week treatment period. Testing of lung function as well as measurement of the levels of inflammatory markers in induced sputum was performed. Results There were significantly fewer patients with ≥1 asthma exacerbation in the theophylline plus SFC group (29.6%) when compared with the SFC plus placebo group (46.9%) ( p = 0.004). Theophylline plus SFC improved the FEF25–75% value, which indicates enhanced small airway function, to a greater extent than SFC plus placebo (66.9 ± 18.8% and 57.4 ± 17.6%, respectively; p < 0.001). A significant decrease in eosinophil count and concentration of eosinophil cationic protein in induced sputum was also seen in the theophylline plus SFC group when compared with the SFC plus placebo group (4.1 ± 2.2% and 6.3 ± 2.7%, 63.6 ± 39.5 μg/L and 89.4 ± 45.6 μg/L, respectively; all p < 0.01). Conclusion The combination of theophylline plus SFC may provide greater protection against asthma exacerbations, and its administration is accompanied by significant improvements in small airway function and airway inflammation.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>23290154</pmid><doi>10.1016/j.rmed.2012.12.004</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0954-6111 |
| ispartof | Respiratory medicine, 2013-03, Vol.107 (3), p.347-354 |
| issn | 0954-6111 1532-3064 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1312174652 |
| source | MEDLINE; Elsevier ScienceDirect Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Adolescent Adult Aged Airway inflammation Albuterol - analogs & derivatives Albuterol - therapeutic use Androstadienes - therapeutic use Asthma Asthma - drug therapy Asthma - metabolism Asthma - physiopathology Bronchodilator Agents - therapeutic use Circadian Rhythm - physiology Drug Combinations Drug dosages Drug Therapy, Combination Female Fluticasone-Salmeterol Drug Combination Glucocorticoids - therapeutic use Hospitals Humans Inflammation Mediators - metabolism Male Middle Aged Peak Expiratory Flow Rate - drug effects Peak Expiratory Flow Rate - physiology Pulmonary/Respiratory Respiratory Mechanics - drug effects Respiratory Mechanics - physiology Salmeterol/fluticasone propionate combination product Small airway function Sputum - chemistry Standard deviation Theophylline Theophylline - therapeutic use Treatment Outcome Young Adult |
| title | Efficacy of theophylline plus salmeterol/fluticasone propionate combination therapy in patients with asthma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T21%3A37%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20of%20theophylline%20plus%20salmeterol/fluticasone%20propionate%20combination%20therapy%20in%20patients%20with%20asthma&rft.jtitle=Respiratory%20medicine&rft.au=Nie,%20Hanxiang&rft.date=2013-03-01&rft.volume=107&rft.issue=3&rft.spage=347&rft.epage=354&rft.pages=347-354&rft.issn=0954-6111&rft.eissn=1532-3064&rft_id=info:doi/10.1016/j.rmed.2012.12.004&rft_dat=%3Cproquest_cross%3E1312174652%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1289064671&rft_id=info:pmid/23290154&rft_els_id=S0954611112004544&rfr_iscdi=true |